Drug Approval | May 08, 2025
Lupin launches Eslicarbazepine Acetate tablets in US
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
The transaction enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
The FDA issued Form 483 with one observation related to building and facility management
The Q1 2025 also witnessed a successful launch of Allegra D
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
